US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Lantern Pharma Inc.

< Previous 1 2 3 4 Next >
News headline image
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
< Previous 1 2 3 4 Next >